Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis

Neoplasia

Volumn 9, Issue 8, 2007, Pages 678-688

  Entz Werle, Natacha ^a,b   Lavaux, Thomas ^b   Metzger, Nadia ^a   Stoetzel, Corinne ^c   Lasthaus, Christelle ^b   Marec, Perrine ^d   Kalifa, Chantal ^e   Brugieres, Laurence ^e   Pacquement, Hélène ^f   Schmitt, Claudine ^g   Tabone, Marie Dominique ^h   Gentet, Jean Claude ⁱ   Lutz, Patrick ^b   Babin, Annie ^b   Oudet, Pierre ^b   Gaub, Marie Pierre ^a,b   Perrin Schmitt, Fabienne ^c  

^a INSERM   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f INSTITUT CURIE   (France)

^g CHU NANCY BRABOIS   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ TIMONE HOSPITAL   (France)

Author keywords

APC; MET; Osteogenesis; Pediatric osteosarcoma; TWIST

Indexed keywords

APC; FIBROBLAST GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR TWIST;

ADULT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOSARCOMA; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOOD COAGULATION FACTORS; BONE NEOPLASMS; CHILD; HUMANS; NUCLEAR PROTEINS; OSTEOGENESIS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, CELL SURFACE; RECEPTORS, GROWTH FACTOR; TWIST TRANSCRIPTION FACTOR;

EID: 34548259435     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07367     Document Type: Article

References (50)

1. Ducy P (2001). Contrôle génétique de la squelettogenèse. Med/Sci 17, 1245-1251.
2. Karsenty G (1998). Genetics of skeletogenesis. Dev Genet 22, 301-313.
3. Rice D, Aberg T, Chan YS, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE, and Thesleff I (2000). Integration of FGF and TWIST in calvarial bone and suture development. Development 1237, 1845-1855.
4. Rice D, Rice R, and Thesleff I (2003). Molecular mechanisms in calvarial bone and suture development, and their relation to craniosynostosis. Eur J Orthod 25, 139-148.
5. Eames BF, De la Fuente L, and Helms JA (2003). Molecular ontogeny of the skeleton. Birth Defects Res C Embryo Today 69, 93-101.
6. Colnot C (2005). Cellular and molecular interactions regulating skeletogenesis. J Cell Biochem 95, 688-697.
7. El Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, Bourgeois P, Bolcato-Bellemin AL, Munnich A, and Bonaventure J (1997). Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 15, 42-46.
8. Lefebvre V and De Crombrugghe B (1998). Toward understanding SOX9 function in chondrocyte differentiation. Matrix Biol 16, 529-540.
9. Nasaki MC, Wang Q, Xu J, and Ornitz DM (1996). Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13, 233-236.
10. Coffin JD, Florkiewicz RZ, Neumann J, Mort-Hopkins T, Dorn GW II, Lightfoot P, German R, Howles PN, Kier A, and O'Toole BA (1995). Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol Biol Cell 6, 1861-1873.
11. Weir EC, Philbrick WM, Amling M, Neff LA, Baron R, and Broadus AE (1996). Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc Natl Acad Sci USA 93, 10240-10245.
12. Zelzer E, Glotzer DJ, Hartmann C, Hartmann C, Thomas D, Fukai N, Soker S, and Olsen BR (2001). Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 106, 97-106.
13. Ducy P (2000). A molecular switch in osteoblast biology. Dev Dyn 219, 461-471.
14. Blanquaert F, Delany AM, and Canalis E (1999). Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. Endocrinology 140, 1069-1074.
15. Hartmann C (2006). A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol 16, 151-158.
16. Reinhold MI, Kapadia RM, Liao Z, and Naski MC (2006). The Wnt-inducible transcription factor Twist1 inhibits chondrogenesis. J Biol Chem 281, 1381-1388.
17. Hernandez S, Lopez-Knowles E, Lloreta L, Kogevinas M, Amoros A, Tardon A, Carrato A, Serra C, Malats N, and Real FX (2006). Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24, 3664-3671.
18. St Bernard R, Zheng L, Liu W, Winer D, Asa SL, and Ezzat S (2005). Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146, 1145-1153.
19. Thussbass C, Nahriq J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoeffler H, Ullrich A, et al. (2006). FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24, 3747-3755.
20. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt N, Knyazeva T, Muller S, Gartner S, Sures I, et al. (2002). Cancer progression and tumor cell motility are associated with the FGFR4Arg388 allele. Cancer Res 62, 840-847.
21. Mendoza S, David H, Gaylord GM, and Miller CW (2005). Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes. Cancer Genet Cytogenet 158, 142-147.
22. Elias MC, Tozer KR, Silber JR, Mikheeva S, Denq M, Morrison RS, Manning TC, Silbergeld DL, Glackin CA, Reh TA, et al. (2005). TWIST is expressed in human gliomas and promotes invasion. Neoplasia 9, 824-837.
23. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, et al. (2005). Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65, 5153-5162.
24. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savaqner P, Gitelman I, Richardson A, and Weinberg RA (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939.
25. Hadjihannas MV, Bruckner M, Jerchow B, Birchmeier W, Dietmaier W, and Behrens J (2006). Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer. Proc Natl Acad Sci USA 103, 10747-10752.
26. Yoshikawa H, Nakase T, Myoui A, and Ueda T (2004). Bone morphogenetic proteins in bone tumors. J Orthop Sci 9, 334-340.
27. Morimoto Y, Ozaki T, Ouchida M, Umehada N, Ohata N, Yoshida A, Shimizu K, and Inoue H (2003). Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98, 2245-2250.
28. Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M, and Comoglio PM (1995). The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10, 739-749.
29. Entz-Werle N, Schneider A, Kalifa C, Voegeli AC, Tabone MD, Marecberard P, Marcellin L, Pacquement H, Terrier P, Boutard P, et al. (2003). Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping. Br J Cancer 88, 1925-1931.
30. Entz-Werle N, Stoetzel C, Berard-Marec P, Kalifa C, Brugieres L, Pacquement H, Schmitt C, Tabone MD, Gentet JC, Quillet R, et al. (2005). Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer 117, 349-355.
31. Tenta R, Sourla A, Lembessis P, and Koutsilieris M (2006). Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Anticancer Res 26, 283-804.
32. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, and Redini F (2005). Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104, 2522-2529.
33. Heymann D, Ory B, Gouin F, Green JR, and Redini F (2004). Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 10, 337-443.
34. Schneider A, Borgnat S, Lang H, Regine O, Lindner V, Kassem M, Saussine C, Oudet P, Jacqmin D, and Gaub MP (2000). Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res 60, 4617-4622.
35. Streit S, Bange J, Fitchner A, Ihrler S, Issing W, and Ullrich A (2004). Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111, 213-217.
36. Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-berard P, Entz-Werle N, Schmitt C, Brugieres L, Vanel D, et al. (2007). SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43, 752-761.
37. Entz-Werle N, Gaub MP, Lavaux T, Marcellin L, Metzger N, Marecberard P, Schmitt C, Brugieres L, Kalifa C, Tabone MD, et al. (2007). Kit gene in pediatric osteosarcomas: could it be a new therapeutic target? Int J Cancer 120, 2510-2516.
38. Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, and Abounader R (2005). The scatter factor/hepatocyte growth factor: c-Met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 65, 9355-9362.
39. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, et al. (2006). Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66, 352-361.
40. Pajer P, Pecenka V, Karafiat V, Kralova J, Horejsi Z, and Dvorak M (2003). The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma. Oncogene 22, 665-673.
41. Puisieux A, Valsesia-Wittmann S, and Ansieau S (2006). A twist for survival and cancer progression. Br J Cancer 94, 13-17.
42. Zauber PN, Sabbath-Solitare M, Marotta SP, and Bishop DT (1999). K-ras mutation and loss of heterozygosity of the adenomatous polyposis coli gene in patients with colorectal adenomas with in situ carcinoma. Cancer 86, 31-36.
43. Grumbles RM, Howell DS, Wenger L, Altman RD, Howard GA, and Roos BA (1996). Hepatocyte growth factor and its actions in growth plate chondrocytes. Bone 19, 255-261.
44. Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, et al. (2006). MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 66, 4750-4757.
45. Qiu WA, Zhou BS, Chu PG, Chen WG, Chung C, Shih J, Hwu P, Yeh C, Lopez R, and Yen Y (2005). Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol 11, 5266-5272.
46. Mhawech-Fauceglia P, Cheney R, Fischer G, Beck A, and Hermann FR (2006). FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 32, 231-237.
47. Sasaki T, Arai H, Beppu T, and Ogasawara K (2003). Detection of gene amplification and deletion in high-grade gliomas using a genome DNA microarray (GenoSensor Array 300). Brain Tumor Pathol 20, 59-63.
48. Wang J, Stockton DW, and Ittmann M (2004). The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10, 6169-6178.
49. Sessa C, Vigano L, Grasselli G, Trigo J, Marimon I, Llado A, Locatelli A, Ielmini N, Marsoni S, and Gianni L (2006). Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 42, 171-178.
50. Wood JM (2000). Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Medecina 60, 41-47.